SI-BONE (SIBN) said late Monday it received a 510(k) clearance from the US Food and Drug Administration for the iFuse Granite Onyx system to treat screw loosening in spinal fusion procedures, especially in patients with low bone density.
The system allows for rapid osseointegration and lower micromotion to aim for early fixation and reduced screw loosening, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.